We are not just advancing research — we are accelerating Hope.
Today's research is moving beyond a one-size-fits-all treatment toward therapies tailored to each patient's unique cancer biology, improving survival and quality of life. Rexanna's Foundation is committed to accelerating these breakthroughs — funding research that changes what is possible.
Seed Grants That
Multiply Impact
There is good news in the advancement of lung cancer research. New treatments are being discovered that can be used alone, before, after, or in combination with traditional chemotherapy, radiation, and surgery.
To date Rexanna's Foundation has given over $1.6 million dollars to targeted research projects within the Thoracic Department of The University of Texas MD Anderson Cancer Center. Funding from Rexanna's Foundation has enabled the thoracic team to generate over $20M+ in additional grant funding. .
Targeting IL-1α for Interception of KRAS-Driven Lung Pre-Cancer / Combined with Elucidating the Molecular Mechanisms of Sexual Dimorphism in Lung Cancer following Environmental Exposures.
Investigating the mechanisms of treatment resistance and therapeutic vulnerability of brain metastases in KRAS-inhibitor resistant non-small cell lung cancer.
Optimizing Lung Cancer Treatment using artificial intelligence. Matching grant gift provided by Rusty Rush.
Survivorship through the MD Anderson Young-Onset Lung Cancer (YOLC) Program: Promoting Wellness, Surveillance, and Long-term Health.
Elucidating how B-to-T Cell Interactions Shape the Response of Early-Stage Non-Small Cell Lung Cancer to Immunotherapy.
Prediction and Biomarker Identification in Tissue and Liquid Biopsies for EGFR-driven resistance mechanisms.
Innovative engineered T cell therapy with 21 validated T cell receptors showing in vitro tumor-killing efficacy, building toward Phase I clinical trials at MD Anderson.
Characterizing ALK fusion resistant mutations to predict efficacy to current and next generation ALK inhibitors, providing a treatment roadmap for clinicians.